Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824836 | 0.91 | ALDH1A1 (0.37) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL5156872 | 0.81 | CYP3A4 (0.37) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL8407409 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL295477 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL2127105 | 0.75 | VCAM1 (0.36) | SMN1; SMN2VCAM1HSPA5 | |
| SCHEMBL6912228 | 0.74 | VCAM1 (0.49) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL8094382 | 0.74 | ALDH1A1 (0.45) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL3999963 | 0.73 | ATM (0.48) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL10743671 | 0.73 | POLB (0.46) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL17171717 | 0.72 | ALDH1A1 (0.44) | ALDH1A1CA2POLBTYRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | ALDH1A1 1788/4885CA2 1579/4885POLB 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.